BioCentury reported an accelerating wave of programs targeting the KRAS G12D mutation, with more than 20 initiatives launched in the past year across biotech and Big Pharma. Companies are advancing diverse modalities—small molecules, covalent inhibitors, and targeted degraders—toward clinics in multiple hard‑to‑treat cancers where G12D is frequent, including pancreatic and colorectal tumors. The surge reflects both improved chemistry against mutant KRAS and renewed investor interest after clinical validation of other KRAS alleles. Developers face familiar hurdles—tumor heterogeneity, resistance mechanisms, and combination‑therapy design—but the crowded field increases the chance one or more candidates will reach regulatory milestones in the coming years. KRAS G12D is a single amino‑acid substitution in the KRAS oncogene that drives tumor growth by locking the protein in an active signaling state; drugging this allele has been a long‑standing oncology priority.